We are live on ! Find out more
IMMU

Immunomedics Inc
IMMU

Delisted

IMMU was delisted on the 22nd of October, 2020.

204 hedge funds and large institutions have $2.38B invested in Immunomedics Inc in 2019 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 85 increasing their positions, 51 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

570% more call options, than puts

Call options by funds: $75.3M | Put options by funds: $11.2M

67% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 51

12% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 26

0% more funds holding

Funds holding: 204204 (0)

29% less capital invested

Capital invested by funds: $3.37B → $2.38B (-$992M)

36% less funds holding in top 10

Funds holding in top 10: 117 (-4)

Holders
204
Holders Change
Holders Change %
0%
% of All Funds
4.43%
Holding in Top 10
7
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-36.36%
% of All Funds
0.15%
New
29
Increased
85
Reduced
51
Closed
26
Calls
$75.3M
Puts
$11.2M
Net Calls
+$64M
Net Calls Change
+$13.6M
Name Holding Trade Value Shares
Change
Change in
Stake
UBS AM
26
UBS AM
Illinois
$17.9M +$2.85M +189,241 +17%
FLAM
27
First Light Asset Management
Minnesota
$17M -$2.73M -181,230 -13%
PAM
28
Panagora Asset Management
Massachusetts
$16.4M +$8.42M +559,594 +90%
Goldman Sachs
29
Goldman Sachs
New York
$14.9M -$1.06M -70,662 -6%
Charles Schwab
30
Charles Schwab
California
$14.9M +$1.21M +80,142 +8%
VOYA Investment Management
31
VOYA Investment Management
Georgia
$14.8M +$2.35M +156,299 +17%
RHJA
32
Rice Hall James & Associates
California
$13.8M +$5.23M +347,781 +54%
EAM
33
Eventide Asset Management
Massachusetts
$13.4M -$6.71M -446,000 -32%
Franklin Resources
34
Franklin Resources
California
$12.6M
RSCM
35
Rock Springs Capital Management
Maryland
$12.4M +$1.43M +95,000 +12%
RPAM
36
Rhenman & Partners Asset Management
Sweden
$11.8M +$3.54M +235,000 +38%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$11.7M +$1.53M +101,534 +14%
O
38
OrbiMed
New York
$11.3M -$51.9M -3,452,203 -81%
Bank of America
39
Bank of America
North Carolina
$10.2M -$9.33M -619,950 -46%
CS
40
Candriam SCA
Luxembourg
$10.1M -$3.09M -205,487 -22%
FCM
41
Frontier Capital Management
Massachusetts
$9.54M -$5.99M -398,237 -37%
N
42
Nuveen
North Carolina
$9.29M +$10.1M +670,129 New
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$8.72M +$2.03M +134,873 +27%
Marshall Wace
44
Marshall Wace
United Kingdom
$8.35M +$9.06M +602,116 New
GTC
45
Ghost Tree Capital
New York
$8.32M -$3.01M -200,000 -25%
Macquarie Group
46
Macquarie Group
Australia
$8.04M -$4.21M -280,000 -33%
Invesco
47
Invesco
Georgia
$7.6M +$947K +62,967 +13%
NC
48
Nexthera Capital
New York
$7.27M +$2.85M +189,416 +57%
Deutsche Bank
49
Deutsche Bank
Germany
$7.13M -$916K -60,844 -11%
MMH
50
Menora Mivtachim Holdings
Israel
$7.07M

IMMU Hedge Fund Activity: Q2 2019 in Review

204 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q2 2019, worth a combined $2.38B — down 29% from $3.37B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new IMMU positions and 26 closed out — a net gain of 3 holders — while 85 added to existing stakes and 51 trimmed.

The largest buyer was Avoro Capital Advisors, adding an estimated $49.4M. The largest seller was Fidelity Investments, cutting an estimated $153M.

  • 204 institutional investors held Immunomedics Inc (IMMU) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $2.38B of Immunomedics Inc stock for Q2 2019, down 29% quarter-over-quarter.
  • 29 funds opened new Immunomedics Inc positions in Q2 2019 and 26 closed out, a net change of +3 holders.
  • The largest Immunomedics Inc buyer in Q2 2019 was Avoro Capital Advisors, an estimated $49.4M added.
  • The largest Immunomedics Inc seller in Q2 2019 was Fidelity Investments, an estimated $153M sold.

Based on aggregated 13F filings for Q2 2019.